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Chapter XXVIII

Hyperandrogenism and Obesity:
Ominous Co-Morbidities
Amit M. Deokar, Shawn J. Smith, Amanda J. Goodwin and
HatimA. Omar
Division of Adolescent Medicine, Department of Pediatrics, University ofKentucky,
Lexington, KY, USA

Abstract
This review has a two-fold objective. One, it addresses the association of
hyperandrogenism and obesity and the complex metabolic derangements that are part of
the problem. Clinical management of these co-morbidities is challenging and complex.
Second, this article will aid health care providers with the key features to an early
diagnosis and intervention to decrease the morbidities in the short as well as long term.
Method: Systematic review of articles and information on the topic of interest that were
published in the last 15 years. Conclusion: Obesity and hyperandrogenism are integral
parts of Metabolic Syndrome/Polycystic Ovarian Syndrome (PCOS)!Hyperandrogenism,
Insulin resistance, and Acanthosis Nigricans (HAIR-AN). With the childhood obesity
epidemic, the metabolic syndrome and the associated abnormalities are routinely seen in
clinical practice and these have a tremendous economic burden on the society and the
quality of life.

Keywords: Adolescence, obesity, metabolic syndrome, hyperandrogenism, polycystic
ovarian syndrome, hyperandrogensim, insulin resistance, acanthosis nigricans.
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Introduction
Obesity in children and adolescents has increased at an alarming rate in the last two
decades. Over the years, researchers have acquired a better understanding about the strong
association of obesity in metabolic syndrome (MS, previously known as metabolic syndrome
X) (1). Patients with MS have various metabolic abnormalities that can include abnormal
glucose and insulin ratio, insulin resistance, high blood pressure, altered lipid profile, prothrombotic and pro-inflammatory state. Teenagers with MS are predisposed to long term
morbidities, such as early coronary artery disease, hepatic steatosis, type 2 diabetes, and
stroke (1). Evidence suggests that an overweight teenager has an 80 percent chance of
continuing to be overweight in the adult life (2).
Approximately 17 percent of children aged 2-19 years are considered overweight based
on a survey by National Health and Nutrition Examination Survey of 2003-2004 (3). As
noted earlier, the rate of obesity has doubled in adolescents, who are in the 12-19 year age
group (4). The prevalence of obese and overweight children may be different depending on
the gender and ethnicity. For example, the obesity rates are higher in African Americans,
Hispanic Americans, males, and those living in the southern states (2). The definition of
obesity varies in adolescents when compared to adults due to different proportion of body fat
in boys and girls at different ages (5). Body Mass Index (BMI) is a reliable tool to assess
obesity, because it is easy to obtain and correlates well with the body fat (6). Any adolescent
with a BMI of 30 kg/m 2 or 95th percentile for gender and age falls in the overweight
category. They are considered at risk of being overweight if their BMI is between 85th and =
95th percentile. In the US, the economic burden of direct and indirect healthcare cost due to
obesity and co-morbidities is estimated to be well over $ 117 billion annually. As the obesity
rates have doubled and tripled respectively in children and adolescents, so have the health
care costs (7). This impacts the healthcare burden directly.
Obesity and hyperandrogenism (HA) are strongly associated in patients who have been
diagnosed to have polycystic ovarian syndrome (PCOS)/HA/MS. This article addresses their
relationship with one another and specific management options. A subset of (PCOS) includes
hyperandrogenism, insulin resistance and acanthosis nigricans, abbreviated as HAIR-AN
(8,9). Historically PCOS was described based on findings of multiple cysts in the ovaries,
irregular or no menstrual periods, and hirsuitism. However, absence of ovarian cysts does not
rule out this syndrome (10). Women with high androgen levels have associated HAIR-AN
features in about 5-10 percent of cases (11). The onset of PCOS/HAIR-AN may occurs in
adolescent years and the diagnosis is likely to be delayed until early adulthood (8,9).

Pathophysiology
As PCOS/HAIR-AN is being studied more over the last two decades, different theories
have been proposed to explain the features of the syndrome, including obesity. The primary
problem in HA appears to be due to an altered hypothalamo-pituatary-ovarian axis. The
anovulation and thus abnormal or absence of menstrual periods is from a persistent
leutenizing hormone (LH) surge and its high concentration in the blood. There is also an
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increased GnRH surge as the negative feedback from estrogen and progesterone is ineffective
due to relative hypothalamic insensitivity. The LH surge results in increased production of
androgens. The level of follicle stimulating hormone (FSH) is less when compared to the LH
resulting in decreased enzymatic (aromatase) conversion of androgen to estrogen and thus
anovulation.
Another key association of HA is hyperinsulinsm. This is due to peripheral insulin
resistance, which can result in a hyperglycemic state. The level of sex hormone binding
globulin (SHBG) is decreased due to the high insulin levels and consequently there is a rise
in the free testosterone level (8). Insulin also increases the androgen production by directly
stimulating the theca cells (12). Both hyperinsulinism and HA predispose an individual to
have an athrogenic lipid profile. Total cholesterol, triglycerides (TO) levels are also elevated.
Increased activity of the enzyme lipase affects the cholesterol metabolism and could result in
a decreased level of the high density lipoprotein-cholesterol (HDL-C) (13). Another
postulated mechanism for HAIR-AN is a genetic mutation of the insulin receptor (tyrosine
kinase domain) (9).
Effects of HA can be multi-fold. Even though increased androgen production in women
is associated with obesity, one study in 2002 by Gapstur et al (14) in obese men have found
to have lower testosterone and dehydroepiandroterone sulfate (DHEAS) levels. High
androgen levels in children and adolescents are linked to precocious pubetty, accelerated
bone growth, height, features of PCOS, and are more commonly seen in obese subjects
compared to non-obese. In pre-pubettal obese children the level of DHEAS is often elevated
(14).
Recently, researchers have looked at the effects of proteins like adiponectin, resistin,
leptin, and TNF-a on the fat metabolism, peripheral insulin resistance, and energy
expenditure (15). Resistin is produced by the mature visceral and subcutaneous adipocytes
and influences insulin sensitivity. Adiponectin and leptin, also secreted from the adipocytes,
have similar roles ( 16). A recently published study by Shin et al (17) suggested obesity as an
inflammatory process due to findings of increased levels of C-reactive protein (CRP) and
TNF found in obese children. The adiponectin level was found to be much lower
concentration in these children. Retinol Biding Protein 4 (RBP4) is present in omental and
subcutaneous fat and is expressed more in women with PCOS (18). The high levels of
androgen and features of metabolic syndrome have shown to normalize in post-menarche
obese adolescents after weight reduction (19).

Diagnostic Criteria
A standard list of the diagnostic criteria for MS in children and adolescents is still
lacking. However, a modified diagnostic criteria for children using the NCEP criteria and
data from the National Health and Nutrition Examination Survey (NHANES, 1988-94) is
widely used. The National Cholesterol Education Program (NCEP) and the Adult Treatment
Panel III (ATP Ill) include at least 3 of 5 of the following criteria for the diagnosis of MS in
adults (1,2,20,21).
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Abnormal lipid panel: Hypertriglyceridemia (> 150 mg/dl) and low HDL-C
(<40mg/dl in males and <50 in females).
High fasting glucose level. Hyperglycemic state is defined as fasting glucose level of
100 mg/dl or more.
Elevated blood pressure, systolic, diastolic, or both using reference ranges. From
example, blood pressure of > 135/85 mmHg is considered abnormal.
Increased waist circumference/abdominal girth. BMI is fairly reliable in assessing
obesity in children.
High insulin resistance (criterion in children).
The World Health Organization (WHO) criteria required elevated insulin or glucose
level(> llOmg/dl) in addition to at least two of the following :[2]
Abdominal obesity
Waist size >94 em or waist to hip ratio of >0.9
Triglycerides > 150 mg/dl or HDL <35 mg/dl
Blood pressure > 140/90 mmHg.
HAIR-AN is a clinical diagnosis and includes the following, in addition to criteria
mentioned above (9):
(a) Acne, hirsuitism, temporal balding, clitoromegaly, and deepening of voice
(suggestive of high androgen level).
(b) Acrochordons (skin tags), acanthosis nigricans (usually found on the neck, axillae,
and back). These are suggestive of insulin resistance and altered hormonal levels.

Suggested Workup
Anthropometric measurement, vital signs, with a complete history and physical exam
(including genital) is recommended. A detailed family, past medical, and medication history
should also be documented. Laboratory data that may be useful includes, fasting levels of
insulin, glucose (complete metabolic panel to assess liver and renal function), lipid panel,
glucose/insulin ratio, HgAlc, and AM cortisol level. Oral glucose tolerance test (2 hour) is
also recommended to document hyperglycemic state. One test that has high sensitivity and
specificity is the euglycemic hyperinsulinemic clamp. This may be impractical in a clinical
setting due to the time consuming and complex nature of the test (9). A thorough endocrine
evaluation should include thyroid function tests, serum prolactin, DHEA-S, am 17hydroxyprogesterone (17 -OHP), SHBG level, and free and total testosterone. IGF -1 level
may be helpful in a suspected growth hormone producing tumor (22).
In order to establish the diagnosis of PCOS, the presence of multiple ovarian cysts is not
necessary. Likewise, an abdominal/pelvic ultrasound detection of multiple ovarian cysts does
not confirm that diagnosis either. Occasionally a computed tomography (CT) or an MRI of
the abdomen/pelvis may be necessary in situations where there are progressive signs of
hyperandrogenism (22).
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Outcome
Metabolic syndrome (PCOS and HAIR-AN subset) in children can lead to potentially
complicated short and long term medical problems. This exhaustive list includes but is not
limited to the following (6):
Distorted body image and perception
Low self-esteem and depression
Acne
Obesity associated problems like snoring, obstructive sleep apnea, disordered sleep,
gastro esophageal reflux disease (GERD), gall stones, joint pain, exercise
intolerance, features of diabetes, coronary artery disease, and skin changes, etc.
Amenorrhea (predisposing to subsequent inadequate bone mineralization) and
possibly infertility.

Treatment Options
The timeframe for the diagnosis of metabolic syndrome/HAIR-AN to the outcome of the
treatment varies from patient to patient and can be often protracted. A multidisciplinary
approach is often required to address the metabolic as well as the psychological stressors
associated with this syndrome. reatment should be geared toward specific metabolic
abnormalities as well (6,9,23). It is important for the healthcare provider to be aware of the
concerns that teenagers may have when it relates to cosmetic appearance. At a psychological
developmental stage where bodily appearance plays an important role in a teenager's life,
skin related problems such as acanthosis nigricans, acne, and hirsuitism may be quite
troubling (22). This can affect their self-esteem directly. Health care providers should have a
low threshold for referring these teenagers to counseling services.

Lifestyle Modification
Although compliance can play a big role with this approach, it is considered one of the
most favored and successful mode of treatment in obese patients, who also have HA (22).
Weight loss can dramatically improve the ovarian function and decrease the levels of
androgens (24). Different dietary changes such as caloric restriction of carbohydrates or fat
with increased protein intake have been previously studied. There is no sufficient data
available if restriction of carbohydrates is better than that of fat intake. It is therefore prudent
to use the expertise of a dietician or nutritionist who can work with obese/overweight
individuals.
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Medication Management
Typically, in addition to the lifestyle modification, medical treatment may include a
combination of one or more of these therapies such as anti androgens, insulin-sensitizing
agents, combined hormonal contraceptives, bariatric surgery, and complementary and
alternative medicine treatment options. As part of a multidisciplinary approach, psychological
counseling is very crucial.

Insulin-Sensitizing Agents
Biguanide: Metformin (trade names such as Glugophage®, Rhiomet®), a pregnancy
category B drug, has traditionally been used in type 2 diabetes mellitus (DM). From a
glycemic stand point, Metformin interferes with the hepatocyte mitochondrial respiratory
oxidative process and decreases gluconeogenesis. This however, is not a complete blockade
of gluconeogenesis. It also facilitates the glucose transport in tissues such as the skeletal
muscles, by activating the enzyme tyrosine kinase (TK) on the insulin receptors and
enhancing the glucose transporter system. Some of this action is also on the adipocytes. It
also acts against the gluconeogenic effects of glucagon. Metformin is particularly useful in
obesity associated with HA. Due to its insulin lowering effect, there is a consequent decrease
in the free and total testosterone and an increase in the estradiol level (25). This has a
beneficial effect on ovulation, hirsuitism and acne.
As obesity is strongly associated with cardiovascular morbidity and mortality, metformin
has an added benefit of being cardioprotective. It has shown to decrease the free fatty
oxidation, which helps improve the insulin sensitivity as well. It may also help lower the total
cholesterol (TC), very low density lipopoprotein cholesterol (VLDL-C), low density
lipoprotein cholesterol (LDL-C), and increase the high density lipoprotein cholesterol (HDLC). It also lowers the platelet aggregation and adhesion, and decreases the levels of tissue
plasminogen inhibitor 1 and von Willebrand factor. This has a positive effect on homeostasis
(26). It can induce vascular relaxation and reduce the oxidative stress (25,26). A combination
of flutamide (an androgen receptor blocker) and metformin with an addition of drosperinone
(a 4th generation progesterone) has shown to decrease abdominal fat (27).
Usual side effects from metformin may include gastrointestinal symptoms such as
nausea, flatulence and diarrhea. These may be reduced by taking it with food. Treatment may
be started with a single daily dose, preferably at a lowest possible dose. It may then be
increased to a twice daily dose. It is not recommended to go over the maximum dosage of
2.25 grams/day (25). One must be aware of the potential toxicity from metfromin that
includes lactic acidosis in rare situations. Metformin is fairly .safe for the mother and baby
during pregnancy and lactation (28).
Thiazolidinediones: Rosiglitazone is an insulin sensitizing agent, whose action on the
peroxisome proliferator-activated receptor (PPAR ) on the adipocytes improves glucose
transport into the cell by increasing the adiponectin secretion (29). In studies done earlier on
overweight women with PCOS, there was a decrease in the insulin resistance and return of
ovulation as indicated by regular menses. The SHBG level also shows an increase that helps
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with the ovulation. Some of the side effects include weight gain and cardiac failure in
susceptible individuals (30).

Regulation of the Hormonal/Androgen Imbalance and Use of Oral
Contraceptives
Combination birth control pills (BCP's) are the cornerstone in the treatment ofHA. Their
mechanism of action includes the following:
Increase the SHBG production and level: This allows a reduction of free
testosterone.
Suppress LH: Decreases androgen production from the ovaries.
Anti-minerelocorticoid activity: Certain progestins such as Drosperinone have low
androgenic activity and are generally preferred in HA. The brand name
contraceptives Yasmin® and Ortho-Tri-Cyclen® contain Drosperinone.
The effects of combination BCP's include normalization of menses and a decrease in
acne and hirsuitism (22). In addition to the above, other pharmacologic agents have been
tried in HA states are cyproterone acetate, finastreride, glucocorticoid, such as prednisone
(patients with late onset congential adrenal hyperplasia (CAH) having PCOS features), and
spironolactone.

Surgical Options
Bariatric Surgery: A decrease in obesity-related morbidity has been well documented in
individuals that have undergone Roux-en-Y gastric bypass surgery. Although this is an
optional procedure that has been evaluated mostly in morbidly obese adults, the guidelines
are quite conservative for the adolescent population. Morbidly obese teenagers, who have
failed the non-surgical approach may be considered for a gastric bypass surgery. Other
justifications in addition to the above includes a BMI of 40 kg/m2 or more, physical and
psychosocial co morbidities from obesity (31 ). Bariatric surgery intended to result in weight
loss can positively impact obesity, PCOS, and reverse anovulation. The risks from obesity
during pregnancy in morbidly obese teens is also decreased by the procedure (31 ). A I to 2
year wait post operatively for becoming pregnant is usually recommended. As there can be
potential complications from this surgical procedure, careful multidisciplinary evaluation for
the need for surgery is needed.

Complementary and Alternative Medicine
Alternative approaches in the treatment of PCOS have been recently gaining popularity.
In view of side effects from the traditional medical and surgical treatment, researchers have
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looked at the benefits of acupuncture, a traditional form of Chinese medicine. Acupuncture
has been shown to modulate neuro-endocrine systems that results in lowering of the increased
sympathetic tone in individuals with PCOS . By releasing B-endorphins the technique of
acupuncture can directly influence the HP A axis and lower the cortisol and LH levels (32).
As a result, its beneficial effects on metabolic, ovulation, and other neuro-endocrinal
endogenous systems can positively influence the features of PCOSIHA. Other forms of
alternative medicine such as homeopathy, Ayurveda, diet supplements, and hypnotherapy
have been tried to treat obesity in adults with some encouraging results even though some are
not very convincing (33).

Federal/State Program
The CDC (Center for Disease Control and Prevention), the Division of Nutrition and
Physical Activity (DNP A) and the health departments of 28 states have established the
Nutrition and Physical Activity Program to Prevent Obesity and Other Chronic Diseases
(NPAO) since 1999 using the social ecological model (34} Healthcare providers are
encouraged to contact their individual health departments to learn more about the program,
where available.

Conclusions
Metabolic syndrome, hyperandrogenism, and PCOS are integral part of complex
metabolic abnormalities that have a great impact on the health and general well-being of an
individual. The diagnosis is often late and this adds to the economic burden from obesity
related problems. The following key points will aid the healthcare provider with the timely
diagnosis ofHA/MS/PCOS and appropriate interventions.
Healthcare provider awareness of obesity in childhood and adolescence.
Utilizing diagnostic criteria and/or clinical diagnosis of PCOS/HA/MS. One may
refer to the NCEP, NHANES, ATP III, WHO diagnostic criteria.
A complete history, including that of the individual, family, past, and medications.
Complete physical exam. As noted earlier, the diagnosis of HAIR-AN is clinical.
Laboratory and radiological work up. The list includes fasting insulin, glucose
(complete metabolic panel to assess liver and renal function), lipid ,~panel,
glucose/insulin ratio, HgA1c, and AM cortisol level. Oral glucose tolerance test (2
hour), thyroid function tests, serum prolactin, DHEA-S, am 17-hydroxyprogesterone
(17-0HP), SHBG level, free and total testosterone, IGF-1 level are also
recommended.
Management that includes medical, surgical, lifestyle modification techniques, and
appropriate referrals to other sub-specialty providers for addressing associated co
morbidities. Keeping in mind that some patients may desire to utilize alternative and
complimentary medicine options as well.
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Multidisciplinary approach that includes, the primary care provider, sub-specialist,
social worker, nutritionist, and counselor/psychologist.
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